Results for: Zydus Lifesciences

Zydus Lifesciences has secured a non-exclusive patent license from Takeda Pharmaceutical to market Vonoprazan, a novel Potassium Competitive Acid Blocker (P-CAB), in India for the treatment of gastroesophageal reflux disease (GERD). This move expands Zydus’s portfolio of gastrointestinal therapies and offers a new treatment option for patients in India, where GERD is prevalent.

Several companies, including ICICI Prudential Life Insurance, Tata Consumer Products, MCX, Zydus Lifesciences, and M&M Financial Services, are attracting attention from investors. These stocks have been performing well and are expected to continue their positive momentum.